1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 09:19 ET (13:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。